Rigel Pharmaceuticals Provides Preliminary Q4 2025 Revenue of $69.8M and 2026 Outlook of $275-290M

RIGEL PHARMACEUTICALS INC

2025-FY EPS reported $19.48 vs consensus $1.27 ▲ beat (+1431.8%)

Preliminary Q4 2025 total revenue $69.8M, net product sales $65.4M, vs $57.6M and $46.5M in Q4 2024.
Full year 2025 total revenue $294.3M, net product sales $232.0M, up 60% from 2024.
2026 outlook: total revenue $275-290M, net product sales $255-265M, positive net income expected.
R289 Phase 1b study: RBC-TI achieved by 33% (6/18) evaluable patients at doses ≥500 mg QD; enrollment on track for RP2D selection H2 2026.
FDA approved boxed warning for GAVRETO (pralsetinib) for serious infections; postmarketing commitment met.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.